CHU Nancy
Nancy, France
NCT Number: NCT05989399
Antisynthetase syndrome (ASyS) is a rare and heteregeneous overlapping connective tissue disease, characterized by myositis, interstitial lung disease (ILD), joint involvement, Raynaud's phenomenon and cutaneous manifestations ("mechanic's hands"). Over 50% of patients develop ILD, which is the leading cause of death.
The role of neutrophils - innate immune cells involved in inflammatory processes and induced in particular by cytokines of the Th17 pathway - during AS is unknown. Direct pathogenic role of neutrophils has been described during idiopathic inflammatory myopathies, with an increase of netosis correlated with disease activity and muscle damage. During ASyS, a higher number of alveolar neutrophils has been observed in patients with rapidly progressive ILD.
There are few data on the specific evaluation of circulating neutrophils in ASyS. Investigators suppose that circulating neutrophils level could represent a simple and accessible severity biomarker in patients with ASyS.
The main objective is to evaluate the diagnostic performance of the circulating neutrophils level (> 7000/mm3) at diagnosis on ASyS severity.
The secondary objectives are:
* to define a threshold for circulating neutrophils levels at diagnosis allowing to predict ASyS severity and to assess the diagnostic performance of this threshold. * to define a threshold for the circulating neutrophils/lymphocytes ratio at diagnosis allowing to predict ASyS severity and to assess the diagnostic performance of this threshold. * to study the correlation between the level of circulating neutrophils and ASyS severity at diagnosis of the disease. * to study the correlation between the circulating neutrophils/lymphocytes ratio and ASyS severity at diagnosis of the disease. * to compare the circulating neutrophils level at ASyS diagnosis and after 1 year of treatment. * to compare the circulating neutrophils/lymphocytes ratio at ASyS diagnosis and after 1 year of treatment. * to compare patients characteristics according to ASyS severity at diagnosis. * to compare BAL fluid neutrophils level according to ILD severity at ASyS diagnosis in patients with ILD. * to compare BAL fluid neutrophils/lymphocytes ratio according to ILD severity at ASyS diagnosis in patients with ILD.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Nancy, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
evaluation of circulating neutrophils level
Time frame: baseline (J0)
Time frame: baseline (J0)
global severity defined as presence of severe ILD (PaO2 < 600 mmHg or rapidly progressive ILD), and/or presence of severe myositis (bedrest, or MMT8 score < 30, or MRC muscle testing < 3/5, or swallowing disorers, or dysphagia) and/or presence of myocarditis on cardiac MRI
Time frame: baseline (J0)
Time frame: baseline (J0)
Time frame: baseline (J0)
FVC percentage
Time frame: baseline (J0)
DLCO percentage
Time frame: baseline (J0)
Time frame: baseline (J0)
Time frame: 12 months
Time frame: 12 months
Time frame: baseline (J0)
Time frame: baseline (J0)
Central Hospital, Nancy, France
Other
Evaluation of Circulating Neutrophils in Antisynthetase Syndrome: a Multicenter Retrospective Study
Acronym: NEUTROSAS2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05523167
Active Idiopathic Inflammatory Myopathy, Antisynthetase Syndrome
Phoenix, Arizona, United States
View Trial DetailsNCT07662265
Antisynthetase Syndrome, Antisynthetase syndrome
Beijing, Beijing Municipality, China
View Trial DetailsNCT05691725
Antisynthetase Syndrome, Antisynthetase syndrome
Vandœuvre-lès-Nancy, France
View Trial DetailsNCT05979441
Active Idiopathic Inflammatory Myopathy, Antisynthetase Syndrome
Phoenix, Arizona, United States
View Trial Details